Clicky

4D Molecular Therapeutics, Inc.(FDMT)

Description: 4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.


Keywords: Biotechnology Life Sciences Emerging Technologies Biology Antibodies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Of The Human Retina Gene Therapy Products

Home Page: www.4dmoleculartherapeutics.com

FDMT Technical Analysis

5858 Horton Street
EmeryVille, CA 94608
United States
Phone: 510 505 2680


Officers

Name Title
Dr. John F. Milligan Ph.D. Exec. Chairman
Dr. David H. Kirn M.D. Co-Founder, CEO & Director
Ms. Theresa Janke Co-Founder & Chief of Staff
Mr. August J. Moretti Esq., J.D. Chief Financial Officer
Dr. Fred Kamal Ph.D. Pres & COO
Mike Zanoni VP of Investor Relations
Dr. Scott P. Bizily J.D., Ph.D. Chief Legal & HR Officer and Corp. Sec.
Dr. Robert S. Fishman Chief Medical Officer & Therapeutic Area Head of Pulmonology
Dr. Raphael Schiffmann M.D. Sr. VP & Therapeutic Area Head of Cardiology
Dr. Robert Y. Kim M.B.A., M.D. Sr. VP & Clinical Therapeutic Area Head of Ophthalmology

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.0145
Price-to-Sales TTM: 378.8959
IPO Date: 2020-12-11
Fiscal Year End: December
Full Time Employees: 140
Back to stocks